CN106061506A - 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 - Google Patents

包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 Download PDF

Info

Publication number
CN106061506A
CN106061506A CN201580009498.0A CN201580009498A CN106061506A CN 106061506 A CN106061506 A CN 106061506A CN 201580009498 A CN201580009498 A CN 201580009498A CN 106061506 A CN106061506 A CN 106061506A
Authority
CN
China
Prior art keywords
antipsychotic
vmat2 inhibitor
dimethoxy
pyrido
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580009498.0A
Other languages
English (en)
Chinese (zh)
Inventor
塞缪尔·罗杰·杰西·霍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Priority to CN202110257206.2A priority Critical patent/CN113368110A/zh
Priority to CN202110257547.XA priority patent/CN113413385A/zh
Publication of CN106061506A publication Critical patent/CN106061506A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580009498.0A 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 Pending CN106061506A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110257206.2A CN113368110A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
CN202110257547.XA CN113413385A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937223P 2014-02-07 2014-02-07
US61/937,223 2014-02-07
PCT/US2015/014893 WO2015120317A1 (en) 2014-02-07 2015-02-06 Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110257206.2A Division CN113368110A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
CN202110257547.XA Division CN113413385A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN106061506A true CN106061506A (zh) 2016-10-26

Family

ID=52589782

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110257206.2A Pending CN113368110A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
CN201580009498.0A Pending CN106061506A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
CN202110257547.XA Pending CN113413385A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110257206.2A Pending CN113368110A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110257547.XA Pending CN113413385A (zh) 2014-02-07 2015-02-06 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Country Status (12)

Country Link
US (4) US9782398B2 (enExample)
EP (2) EP3102239A1 (enExample)
JP (4) JP6718376B2 (enExample)
KR (1) KR102328058B1 (enExample)
CN (3) CN113368110A (enExample)
AU (1) AU2015213778B2 (enExample)
CA (1) CA2938581C (enExample)
IL (1) IL247127B (enExample)
MX (1) MX378664B (enExample)
NZ (2) NZ760790A (enExample)
RU (2) RU2021128797A (enExample)
WO (1) WO2015120317A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074273A (zh) * 2018-05-04 2020-12-11 韩国原子力医学院 包含阿立哌唑作为活性成分的辐射敏感性增强组合物
US11311532B2 (en) 2017-09-21 2022-04-26 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US11439629B2 (en) 2017-01-27 2022-09-13 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11654142B2 (en) 2017-10-10 2023-05-23 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3936130T1 (sl) * 2014-05-06 2024-05-31 Neurocrine Biosciences, Inc., Režim odmerjanja valbenazina za zdravljenje hiperkinetičnih gibalnih motenj
WO2016127133A1 (en) * 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
ES2811048T3 (es) 2016-06-29 2021-03-10 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US11339158B2 (en) 2017-12-26 2022-05-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
TWI832854B (zh) 2018-04-25 2024-02-21 美商神經治療股份有限公司 丁苯那嗪經皮輸送裝置
TW202011963A (zh) 2018-06-14 2020-04-01 美商紐羅克里生物科學有限公司 Vmat2抑制劑化合物、組合物及其相關方法
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
MA53239A (fr) * 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
WO2020188551A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for treating autism spectrum disorder and associated disorders
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
BR112023026691A2 (pt) * 2021-06-30 2024-03-05 Neurocrine Biosciences Inc Valbenazina para uso no tratamento complementar de esquizofrenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980924A (zh) * 2004-02-11 2007-06-13 剑桥实验室（爱尔兰）有限公司 二氢丁苯那嗪类及包含它们的药用组合物
WO2010026436A2 (en) * 2008-09-08 2010-03-11 Biovail Laboratories International (Barbados) Srl Pharmaceutical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5777697A (en) * 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
WO2000024399A1 (en) 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
PT1855677E (pt) 2005-08-06 2009-01-13 Cambridge Lab Ireland Ltd 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US8524733B2 (en) * 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980924A (zh) * 2004-02-11 2007-06-13 剑桥实验室（爱尔兰）有限公司 二氢丁苯那嗪类及包含它们的药用组合物
WO2010026436A2 (en) * 2008-09-08 2010-03-11 Biovail Laboratories International (Barbados) Srl Pharmaceutical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G REMINGTON ET.AL: "Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial", 《J CLIN PSYCHOPHARMACOL》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439629B2 (en) 2017-01-27 2022-09-13 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11311532B2 (en) 2017-09-21 2022-04-26 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US11654142B2 (en) 2017-10-10 2023-05-23 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN112074273A (zh) * 2018-05-04 2020-12-11 韩国原子力医学院 包含阿立哌唑作为活性成分的辐射敏感性增强组合物
CN112074273B (zh) * 2018-05-04 2023-06-30 韩国原子力医学院 包含阿立哌唑作为活性成分的辐射敏感性增强组合物

Also Published As

Publication number Publication date
KR20160132830A (ko) 2016-11-21
CN113413385A (zh) 2021-09-21
IL247127A0 (en) 2016-09-29
AU2015213778B2 (en) 2020-04-23
JP2019116515A (ja) 2019-07-18
JP2021080294A (ja) 2021-05-27
IL247127B (en) 2021-04-29
KR102328058B1 (ko) 2021-11-17
US20180085364A1 (en) 2018-03-29
CA2938581C (en) 2023-02-28
US9782398B2 (en) 2017-10-10
NZ723107A (en) 2022-11-25
MX2016010071A (es) 2017-04-27
WO2015120317A1 (en) 2015-08-13
MX378664B (es) 2025-03-10
RU2021128797A (ru) 2021-11-26
RU2757221C2 (ru) 2021-10-12
CA2938581A1 (en) 2015-08-13
AU2015213778A1 (en) 2016-08-18
JP2017505316A (ja) 2017-02-16
RU2016135930A (ru) 2018-03-15
JP6718376B2 (ja) 2020-07-08
US20200206215A1 (en) 2020-07-02
NZ760790A (en) 2022-11-25
US20160339011A1 (en) 2016-11-24
EP4049681A1 (en) 2022-08-31
CN113368110A (zh) 2021-09-10
RU2016135930A3 (enExample) 2018-10-05
JP2024003253A (ja) 2024-01-11
EP3102239A1 (en) 2016-12-14
US20190381029A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CN106061506A (zh) 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
US20190015396A1 (en) Vmat2 inhibitors for treating neurological diseases or disorders
US20120035156A1 (en) Combination of glyt1 compound with antipsychotics
WO2013028495A1 (en) Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
EP1480629A1 (en) Combination therapy for treatment of schizophrenia
CN107567444A (zh) 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物
AU2009349456B2 (en) Formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy] - 7-0x0-6, 7- dihydro- 5H- phyrrolo [3, 4-b] pyrazine
US9708315B2 (en) 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
TW201725042A (zh) 用於治療癌症及發炎病症之ｊａｋ抑制劑與ｓｙｋ抑制劑之組合
AU5287499A (en) Use of (S)(-)-amisulpride for the manufacture of a medicament for the treatment of positive, negative, affective or cognitive symptoms of Schizophrenia
HK40062589A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
CA2976258A1 (en) Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
HK40079434A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
EP3027189A1 (en) Method of treating hypertrophic cardiomyopathy
WO2024059659A1 (en) Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
CN102718758A (zh) 喹啉酮衍生物及其作为抗精神分裂症药物的应用
CN117642160A (zh) 精神药剂及其用途
HK1169954A (en) Ph independent formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy] - 7-0x0-6, 7- dihydro- 5h- phyrrolo [3, 4-b] pyrazine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161026